• by:
    • November 16th, 2022
    • Category: whitepaper

    The Value of Quantitative Imaging in COPD Bioequivalence Studies for Biosimilar Development

    This white paper explores the value of using quantitative imaging in respiratory clinical trials.

    White Paper

    The Value of Quantitative Imaging in COPD Bioequivalence Studies for Biosimilar Development

    This white paper explores the value of using quantitative imaging in respiratory clinical trials

    Quantitative analysis of medical imagingin clinical trials for obstructive respiratory diseases can be very beneficial for biosimilar development. In thisarticle Radiomics explores the uses and benefits of medical imaging in respiratory trials in a whitepaper titled "The Value of Quantitative Imaging in COPD Bioequivalence Studies for Biosimilar Development"


    Please fill in your details below and get access to read the full article directly. 

    World COPD Day

    Quantitative analysis of medical imaging in clinical trials for obstructive respiratory diseases can be very beneficial for biosimilar development. In this article Radiomics explores the uses and benefits of medical imaging in respiratory trials in a whitepaper titled "The Value of Quantitative Imaging in COPD Bioequivalence Studies for Biosimilar Development"


    Please fill in your details below and get access to read the full article directly

    Read our other white papers

    Overview news
    radiomics logo
    ISO 13485 Certification
    Go to
    diseases and therapeutic areas
    industry & pharma
    healthcare professionals
    scientific researchers & academia
    Contact
    LégiaPark
    Boulevard Patience et Beaujonc 3
    4000 Liège
    Belgium
    BE.0662.719.440
    [email protected]
    Design: Erinas